TNF and cancer: We can conclude that different treatment protocols that lead to a control of TNFα levels (e.g. treatment with anti-TNF antibodies or with soluble TNF receptor) warrant consideration when designing new cancer therapies utilizing IL-12, without risking its potent antitumor activity.